AI Insight
A large-scale study found that the cardiovascular protective effects of GLP-1 receptor agonist medications like Ozempic, Wegovy, Mounjaro, and Zepbound diminish rapidly after discontinuation. Patients who stopped taking these drugs experienced a 22% increased risk of heart attack, stroke, and death compared to those who continued treatment after a two-year follow-up period.
Why it matters
This research suggests that the cardiovascular benefits of GLP-1 drugs require ongoing treatment and are not sustained after stopping medication. The findings have important implications for treatment planning and highlight that these medications may need to be continued long-term to maintain heart health benefits.
Understand the Science
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
Source: Stopping Ozempic may raise heart attack and stroke risk